TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05550493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The cognitive behavioral therapy program consisted of eight interactive sessions, each requiring approximately 15 minutes to complete. Each ICBT session includes interactive multimedia modules (videos, pictures, and texts), the contents of which were based on the community reinforcement approach. The ICBT sessions covered the following topics: (1) introduction to digital therapeutics and CBT, (2) recognizing the triggers of craving, (3) coping with craving, (4) refusing skills/assertiveness, (5) problem-solving skills, (6) changing thoughts about drugs, (7) seemingly irrelevant decisions, and (8) HIV risks and prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Counseling provided by social workers and psychotherapists on topics including work, family, stress management, and drug craving suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach Bias Modification
Description: In an ApBM session, users were instructed to swipe upward (downward) when they saw portrait (landscape) format images. A shrinking (growing) animation comes after swiping upward (downward) to simulate the visual effect of moving away (moving towards). The images were related to methamphetamine usage (methamphetamine crystals, powders, and paraphernalia) or healthy lifestyles (wealth, sports, gourmet, family activities, etc.). Each ApBM session was composed of presenting each one of the healthy lifestyle (methamphetamine) cues 12 times in landscape (portrait) and once in portrait (landscape).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The DTx application incorporated a game-based cognitive function training module for improving working memory. In this game, a matrix of squares is displayed at the center of the screen. Between 3 and 5 target symbols are randomly placed in the matrix and displayed for 2 seconds. Next, the symbols disappear, and the matrix randomly rotates. The participants were asked to click the correct locations of the target symbols within the prescribed time limit. The game becomes more difficult as the size of the matrix, the number of target symbols, and the complexity of the matrix rotation change at each level. Each cognitive function training session lasted between 3 and 5 minutes.
Study: NCT05357001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue manipulation
Description: to remove muscle spasticity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercises
Description: to remove muscle spasticity
Study: NCT04827680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva MD
Description: The Venus Viva™ MD fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
Study: NCT06256380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive-behavior therapy for adolescents with an eating disorder
Description: Psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based therapy for adolescents with an eating disorder
Description: Psychotherapy
Study: NCT05825573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist
Description: VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care with respect of the international guidelines and recommended dose protocols and will not be specifically supplied for the trial. Anticoagulant treatment will be prescribed for 6 months. The recommended INR target will be \[2-3\] and \[2-2.5\] for patients treated with concomitant antiplatelet therapy. Biological monitoring will be performed at discretion of physicians as usual care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulant
Description: DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care and will not be specifically supplied for the trial. The usual doses of DOA will be prescribed: dabigatran 150mg twice a day, apixaban 5mg twice a day and rivaroxaban 20mg once a day. The adjusted doses (dabigatran 110mg twice a day, apixaban 2.5mg twice a day and rivaroxaban 15mg once a day) will be prescribed according to clinical practice treatment guidelines.
Study: NCT06016777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paraspinal block and patient-controlled intravenous analgesia pump
Description: Patients in this group will receive ultrasound-guided paraspinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinal block and patient-controlled intravenous analgesia pump
Description: Patients in this group will receive ultrasound-guided erector spinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia pump
Description: Patients in this group will not receive regional block. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled intravenous analgesia pump
Description: Patients in this group will not receive regional block. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia pump
Description: Patients in this group will not receive regional block. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
Study: NCT04956913

Intervention type: DEVICE
Intervention: Mac Grath
Description: Patients of this group were intubated using Mac Gath videolaryngoscope

Intervention type: DEVICE
Intervention: Macintosh
Description: Patients of this group were intubated using the Macintosh Laryngoscope
Study: NCT05631483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe
Description: Use of the DAISe Thrombectomy Device
Study: NCT06288100

Intervention type: OTHER
Intervention: Observation
Description: 1. Measure changes in tibial slope after medial opening wedge High tibial osteotomy in Skeletally mature patient with unicompartmental osteoarthitis and genuvarus knee~2. Evaluate the effect of tibial slope angle change on the clinical outcome at 1 year .
Study: NCT05573997

Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers
Description: Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.

Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers
Description: Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.

Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers
Description: Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.
Study: NCT05933382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroid Group
Description: Conventional exercise and corticosteroid injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Group
Description: Conventional exercise and mulligan mobilization
Study: NCT04295278

Intervention type: DIAGNOSTIC_TEST
Intervention: MicroKine Dx system
Description: Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
Study: NCT05819151

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c Test
Description: HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c Test
Description: HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c Test
Description: HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c Test
Description: HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
Study: NCT05201300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate 6 mg/kg/hr
Description: Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate 12 mg/kg/hr
Description: Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
Study: NCT06522139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Episealer Talus Implant
Description: Subjects will be on study for up to 60 months after their talus implant surgery. Treatment: Implantation of Episealer Talus Implant Follow-up: 60 months The total duration of the study is expected to be 75 months. 12 months for subject recruitment, 60 for final subject follow-up and 3 for data analysis and production of the final report.
Study: NCT05042856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PanOptix IOL implantation
Description: All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
Study: NCT05228314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2020S
Description: a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2020S
Description: a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
Study: NCT04666220

Intervention type: OTHER
Intervention: VETC evaluation
Description: We will evaluate VETC presence on tissue specimens

Intervention type: OTHER
Intervention: VETC evaluation
Description: We will evaluate VETC presence on tissue specimens
Study: NCT05242380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell Exercise
Description: The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row.
Study: NCT06266832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, ivgtt, d1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, po, bid, d1-14, Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course Radiation
Description: Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy. The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
Study: NCT05978843

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monetary benefit to purchase fruits and vegetables
Description: Participants will receive varying benefit amounts to purchase fruits and vegetables.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monetary benefit to purchase fruits and vegetables
Description: Participants will receive varying benefit amounts to purchase fruits and vegetables.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monetary benefit to purchase fruits and vegetables
Description: Participants will receive varying benefit amounts to purchase fruits and vegetables.
Study: NCT05903768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Maitland's Mobilization: Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax capsular stretching
Description: Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Anterior, Posterior and inferior capsular stretching would be performed. Each stretch should be held15-30 seconds and repeated 2 to 4 times.
Study: NCT04772612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: sitravatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: sitravatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: sitravatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: sitravatinib
Study: NCT06415136

Intervention type: DEVICE
Intervention: SeaSpine Shoreline
Description: The SeaSpine Shoreline device is a minimally invasive cervical plate/cage system.
Study: NCT06252688

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ambulatory cares in a day-hospital (Lapeyronie, Montpellier) specialized in the evaluation of eating disorders.
Description: All patients assessed in the day-hospital will permormed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensotometry~* Psychiatric assement~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)
Study: NCT04799093

Intervention type: DIAGNOSTIC_TEST
Intervention: EyeBOX
Description: Eye-Tracking based diagnostic

Intervention type: DIAGNOSTIC_TEST
Intervention: EyeBOX
Description: Eye-Tracking based diagnostic
Study: NCT05263778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bempedoic Acid / Ezetimibe Oral Tablet
Description: Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo by mouth once daily for 12 weeks
Study: NCT04372940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Irrigation
Description: Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Irrigation
Description: Saline will serve as the control.
Study: NCT05884541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TipsbyText Messages
Description: Texts sent to caregivers meant to increase parent child interaction around math and literacy, sent to participants 4x a week for 8 months
Study: NCT06254885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Equi-crestal Implant placement
Description: A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is exactly at the same level as the bone of the maxillary/mandibular edentulous crest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-crestal Implant placement
Description: A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is 1mm below the level of the bone crest.
Study: NCT05866809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HK-660S
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06445270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDM Prevention Program
Description: Participants will receive hybrid and group monthly contacts with registered dieticians and lifestyle coaches. Participants will attend monthly in-person physical activity sessions.
Study: NCT06519851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25%
Description: postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) following shoulder surgery by ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interscalene block with 20 ml bupivacaine 0.25%
Description: postoperative analgesic effect of Interscalene block (ISB) following shoulder surgery by ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus
Study: NCT05179356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Dapagliflozin 10 mg given once daily for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04440865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genius® System-assisted Colonoscopy
Description: Genius® Intelligence System is used to assist Colonoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy without Genius® Intelligence System is performed
Study: NCT05985369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet and resistance exercise
Description: Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet and resistance exercise
Description: Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.
Study: NCT05298449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU-045
Description: HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin®
Description: Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
Study: NCT05171556

Intervention type: OTHER
Intervention: Cosmetic product
Description: RV4942A is a face balm product